111 related articles for article (PubMed ID: 4055982)
1. RU 486 inhibits peripheral effects of glucocorticoids in humans.
Gaillard RC; Poffet D; Riondel AM; Saurat JH
J Clin Endocrinol Metab; 1985 Dec; 61(6):1009-11. PubMed ID: 4055982
[TBL] [Abstract][Full Text] [Related]
2. The new steroid analog RU 486 inhibits glucocorticoid action in man.
Bertagna X; Bertagna C; Luton JP; Husson JM; Girard F
J Clin Endocrinol Metab; 1984 Jul; 59(1):25-8. PubMed ID: 6327758
[TBL] [Abstract][Full Text] [Related]
3. Steroid-induced vasoconstriction: glucocorticoid antagonist studies.
Marks R; Barlow JW; Funder JW
J Clin Endocrinol Metab; 1982 May; 54(5):1075-7. PubMed ID: 7061698
[TBL] [Abstract][Full Text] [Related]
4. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome.
Bertagna X; Bertagna C; Laudat MH; Husson JM; Girard F; Luton JP
J Clin Endocrinol Metab; 1986 Sep; 63(3):639-43. PubMed ID: 3734034
[TBL] [Abstract][Full Text] [Related]
5. Blockade of glucocorticoid receptor binding and inhibition of dexamethasone-induced muscle atrophy in the rat by RU38486, a potent glucocorticoid antagonist.
Konagaya M; Bernard PA; Max SR
Endocrinology; 1986 Jul; 119(1):375-80. PubMed ID: 2424746
[TBL] [Abstract][Full Text] [Related]
6. Topical retinoic acid does not alter the vasoconstrictive properties of topical corticosteroids in humans.
Schmied C; Saurat JH
Dermatologica; 1991; 182(2):107-11. PubMed ID: 2050230
[TBL] [Abstract][Full Text] [Related]
7. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
[TBL] [Abstract][Full Text] [Related]
8. The antiglucocorticoid and antiprogestin steroid RU 486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man.
Laue L; Chrousos GP; Loriaux DL; Barnes K; Munson P; Nieman L; Schaison G
J Clin Endocrinol Metab; 1988 Feb; 66(2):290-3. PubMed ID: 2828406
[TBL] [Abstract][Full Text] [Related]
9. Relation of application time to bioactivity of a potent topical glucocorticoid formulation.
Stoughton RB; Wullich K
J Am Acad Dermatol; 1990 Jun; 22(6 Pt 1):1038-41. PubMed ID: 2370328
[TBL] [Abstract][Full Text] [Related]
10. Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
Borelli C; Gassmueller J; Fluhr JW; Nietsch KH; Schinzel S; Korting HC
Skin Pharmacol Physiol; 2008; 21(3):181-7. PubMed ID: 18523415
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of female sexual behavior with intracerebral implants of antiprogestin RU 38486: correlation with binding to neural progestin receptors.
Etgen AM; Barfield RJ
Endocrinology; 1986 Oct; 119(4):1610-7. PubMed ID: 3757904
[TBL] [Abstract][Full Text] [Related]
12. Correlation of the vasoconstriction assay and clinical activity in psoriasis.
Cornell RC; Stoughton RB
Arch Dermatol; 1985 Jan; 121(1):63-7. PubMed ID: 3881088
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoid-induced vasoconstriction in human skin. An inhibitory role on phospholipase A2 activity.
Marks R; Sawyer M
Arch Dermatol; 1986 Aug; 122(8):881-3. PubMed ID: 2874773
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486.
Nieman LK; Chrousos GP; Kellner C; Spitz IM; Nisula BC; Cutler GB; Merriam GR; Bardin CW; Loriaux DL
J Clin Endocrinol Metab; 1985 Sep; 61(3):536-40. PubMed ID: 2991327
[TBL] [Abstract][Full Text] [Related]
15. Correlation of the vasoconstrictor assay and clinical activity in psoriasis.
Woodford R
Arch Dermatol; 1986 Dec; 122(12):1355. PubMed ID: 3789765
[No Abstract] [Full Text] [Related]
16. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
Serup J; Holm P
Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
[TBL] [Abstract][Full Text] [Related]
17. Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women.
Schaison G; George M; Lestrat N; Reinberg A; Baulieu EE
J Clin Endocrinol Metab; 1985 Sep; 61(3):484-9. PubMed ID: 2991322
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid receptor-mediated induction of glutamine synthetase in skeletal muscle cells in vitro.
Max SR; Thomas JW; Banner C; Vitkovic L; Konagaya M; Konagaya Y
Endocrinology; 1987 Mar; 120(3):1179-83. PubMed ID: 2879727
[TBL] [Abstract][Full Text] [Related]
19. The dilution of proprietary corticosteroid ointments--an attempt to evaluate relative clinical potencies.
Gibson JR; Darley C; Kirsch J; Saihan EM; Neild VS
Br J Dermatol; 1982 Apr; 106(4):445-7. PubMed ID: 7073968
[TBL] [Abstract][Full Text] [Related]
20. Effect of RU 486 on the atrophogenic and antiinflammatory effects of glucocorticoids in skin.
Iwasaki K; Mishima E; Miura M; Sakai N; Shimao S
J Dermatol Sci; 1995 Sep; 10(2):151-8. PubMed ID: 8534614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
